A Randomized Open Label Study to Compare the Bioavailability of Lasmiditan 200 mg Under Fed and Fasted Conditions in Healthy Male and Female Subjects

Trial Profile

A Randomized Open Label Study to Compare the Bioavailability of Lasmiditan 200 mg Under Fed and Fasted Conditions in Healthy Male and Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors CoLucid Pharmaceuticals
  • Most Recent Events

    • 19 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Feb 2015, as reported by ClinicalTrials.gov.
    • 01 Feb 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Feb 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top